ArticleBMC psychiatry2025
Dual-target mechanisms of olanzapine in bipolar disorder: a network pharmacology and molecular docking study revealing phase-specific regulation of longevity and PI3K-Akt pathways.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundBipolar disorder (BD) remains a therapeutic challenge due to its clinical heterogeneity and bidirectional mood episodes. While olanzapine is clinically effective in managing BD, its mechanisms in regulating depressive and manic phases remain unclear. This study employs network pharmacology, molecular docking and molecular dynamics (MD) simulation to systematically investigate olanzapine’s polypharmacological mechanisms in BD.
methodsPotential targets of olanzapine were retrieved from GeneCards, SwissTargetPrediction, and PharmMapper. BD-related targets for depression and mania were collected from DisGeNET and GeneCards. Protein-protein interaction (PPI) networks were constructed using STRING and analyzed via Cytoscape. Hub genes were identified using CytoHubba. Functional enrichment (Gene Ontology, GO) and pathway analyses (KEGG) were performed using ClusterProfiler. Molecular docking validated binding affinities between olanzapine and core targets.
resultsA total of 187 and 116 overlapping targets were identified for olanzapine in bipolar depression and mania, respectively. PPI analysis revealed core targets including INS, IGF1, CREB1, PPARG, and PRKACA for bipolar depression, and EGFR, BDNF, GSK3B, IL6, and NTRK1 for mania. KEGG analysis highlighted the longevity regulating pathway (bipolar depression) and PI3K-Akt signaling pathway (mania) as central mechanisms. Molecular docking and MD simulation confirmed strong binding affinities between olanzapine and key targets, mediated by hydrophobic, hydrogen-bond, and π-interactions.
conclusionThis study reveals distinct molecular mechanisms underlying olanzapine’s bidirectional regulation of BD phases. Its antidepressant effects involve neuroplasticity and metabolic modulation via longevity-associated pathways, while anti-manic actions target synaptic and inflammatory signaling through PI3K-Akt cascades. These findings provide a foundation for optimizing BD therapeutics and highlight network pharmacology as a robust tool for dissecting complex drug-disease interactions. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.